GlaxoSmithKline Plc (GSK)

39.52
0.29 0.74
NYSE : Health Technology
Prev Close 39.23
Open 39.50
Day Low/High 39.38 / 39.59
52 Wk Low/High 31.43 / 48.25
Volume 3.75M
Avg Volume 3.18M
Exchange NYSE
Shares Outstanding 2.51B
Market Cap 102.02B
EPS 2.40
P/E Ratio 22.05
Div & Yield 1.97 (4.86%)

Latest News

Revisiting 2 Small-Cap Biotechs

Revisiting 2 Small-Cap Biotechs

They have been wonderful plays for those that have used covered calls on the dips in the stocks as they always seem to rebound.

Adding to an Old Favorite and Taking Some Profits in Cannabis

Adding to an Old Favorite and Taking Some Profits in Cannabis

Aurinia Pharma has some positive catalysts, and I am taking partial gains in cannabis names as they remain strong.

Tough Jobs Stuff, Winter Economic Chill, Vaccine Hiccup, Disney Delights

Tough Jobs Stuff, Winter Economic Chill, Vaccine Hiccup, Disney Delights

Plus, stay nimble as the road just ahead could become a bit more treacherous than many may think.

Mysterious Mnuchin, Vaccines at the Ready, Carnival Isn't Cruising, 2 Big 'W's

Mysterious Mnuchin, Vaccines at the Ready, Carnival Isn't Cruising, 2 Big 'W's

A look at the charts of Advanced Micro Devices and Tesla, plus a review of the 'broadening' market action from Thursday.

Trump's Health and the Market, Charts That Matter, Nvidia News, URI Breaks Out

Trump's Health and the Market, Charts That Matter, Nvidia News, URI Breaks Out

Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.

Jim Cramer: Abbott's Rapid Covid-19 Test and My Super Bowl Dreams

Jim Cramer: Abbott's Rapid Covid-19 Test and My Super Bowl Dreams

Abbott Labs can bring back some normalcy to this country -- and the world -- with its BinaxNOW rapid antigen test along with its amazing Navica app.

Want to Inject Some Growth Into Your Portfolio? Try This Dividend Stock

Want to Inject Some Growth Into Your Portfolio? Try This Dividend Stock

Pfizer is a quality dividend stock that's now trading at a discount.

Jim Cramer: Let's Look Behind the Scenes Amid the Fall

Jim Cramer: Let's Look Behind the Scenes Amid the Fall

Often hidden reasons are lurking below when there's maximum confusion, and here's what they are.

A Healthy Dose of Vaccine and Pharmaceutical Plays

A Healthy Dose of Vaccine and Pharmaceutical Plays

6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.

Across the Pond: 5 ETFs for European Equity Exposure

Across the Pond: 5 ETFs for European Equity Exposure

European markets have been slumping for years, but the time for those countries to shine again may finally be around the corner.

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.

GlaxoSmithKline Is Offering Subtle Clues for Investors

GlaxoSmithKline Is Offering Subtle Clues for Investors

Let's check out the charts of this healthcare stock.

Jim Cramer: Are You a Star Player? Let's Put It to the Test

Jim Cramer: Are You a Star Player? Let's Put It to the Test

Do you know what a company does, does it do it well, and is there anything going on that could change the trajectory?

SPACs Aren't Just for Trading: 2 Attractive Buy and Hold Opportunities

SPACs Aren't Just for Trading: 2 Attractive Buy and Hold Opportunities

I like putting some of my money with incredibly successful folks who are well-connected and have a history of success.

China Headline Risk, Valuation Station and a Workday Play

China Headline Risk, Valuation Station and a Workday Play

WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.

Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago

Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago

So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.

Sell Signals, 'Operation Warp Speed,' Trading Notes

Sell Signals, 'Operation Warp Speed,' Trading Notes

Trump administration taps former GlaxoSmithKline exec as head of vaccine task force, and how I'm playing Walmart and Datadog.

Jim Cramer: Let the Froth Wash Out

Jim Cramer: Let the Froth Wash Out

Let's look at the stocks that will get crushed and that you can't touch right now.

Jim Cramer: Reopening Is Necessary, but Based on Little More Than Hope

Jim Cramer: Reopening Is Necessary, but Based on Little More Than Hope

It's imperative that people get back to work, so we have this great compromise -- let's see how it might play out.

GlaxoSmithKline Charts Prescribe Positive Outlook as It Chases Covid-19 Vaccine

GlaxoSmithKline Charts Prescribe Positive Outlook as It Chases Covid-19 Vaccine

The drugmaker that is partnering with Sanofi to develop a vaccine has seen its shares push higher after declining to a low in late March.

Jim Cramer: Don't Mistake the Rally for Cheering

Jim Cramer: Don't Mistake the Rally for Cheering

There is no joy in stockville -- instead we have big companies with stocks rising. Here's why that is and what you need to understand about the rally amid the crisis.

Taking Stock of Recent Dividend Hikes

Taking Stock of Recent Dividend Hikes

We've seen some high quarterly dividend increases of late, so let's pick out the crème of the crop.

GlaxoSmithKline: The Charts Are Pointing Higher

GlaxoSmithKline: The Charts Are Pointing Higher

Our latest analysis and trading strategy for the the big pharma stock.

5 Best Buys for 2020 from Argus Research

5 Best Buys for 2020 from Argus Research

Analysts from the independent research firm review their picks from last year and share their new favorites.

GlaxoSmithKline Could Trade Up to the $75 Area in the Months Ahead

GlaxoSmithKline Could Trade Up to the $75 Area in the Months Ahead

Let's see what we might expect.

GlaxoSmithKline Could Rise 20% From Here

GlaxoSmithKline Could Rise 20% From Here

Shares of the pharma company have broken out on our Point and Figure chart.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

GlaxoSmithKline Could Be Close to a Major Upside Move

GlaxoSmithKline Could Be Close to a Major Upside Move

The long-term technical view of GSK is very bullish.